| scholarly article | Q13442814 |
| P2093 | author name string | Gouji Toyokawa | |
| Takashi Seto | |||
| Tetsuzo Tagawa | |||
| Takaki Akamine | |||
| P2860 | cites work | The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer | Q27682565 |
| Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib | Q27688906 | ||
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study | Q27852261 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models | Q48450569 | ||
| Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). | Q49188022 | ||
| Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. | Q49662412 | ||
| The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis | Q51740588 | ||
| Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study | Q52580435 | ||
| Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). | Q52666574 | ||
| Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib | Q53739273 | ||
| Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? | Q54378145 | ||
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. | Q54602410 | ||
| Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. | Q54986606 | ||
| Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer | Q88345284 | ||
| ??? | Q27690215 | ||
| Ceritinib in ALK-rearranged non-small-cell lung cancer | Q27852989 | ||
| Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. | Q27853059 | ||
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer | Q27853101 | ||
| Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. | Q27853298 | ||
| Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial | Q27853360 | ||
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 | ||
| Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data | Q30966026 | ||
| Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer | Q33386997 | ||
| The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers | Q33553447 | ||
| Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib | Q33804619 | ||
| RET, ROS1 and ALK fusions in lung cancer | Q34253845 | ||
| Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases | Q35549714 | ||
| PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models | Q35858617 | ||
| Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls | Q36049399 | ||
| Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. | Q36090684 | ||
| The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies | Q36104980 | ||
| Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? | Q36322851 | ||
| P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer | Q36538788 | ||
| ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer | Q37416902 | ||
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | Q37606591 | ||
| Treating ALK-positive lung cancer—early successes and future challenges | Q37999657 | ||
| ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer? | Q38225272 | ||
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. | Q38645064 | ||
| Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial | Q38787993 | ||
| Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP. | Q38906188 | ||
| Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases | Q38957939 | ||
| HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. | Q39252149 | ||
| Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. | Q39285861 | ||
| Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. | Q39354188 | ||
| Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. | Q39586490 | ||
| The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema | Q43223136 | ||
| A novel fusion of TPR and ALK in lung adenocarcinoma | Q46578009 | ||
| Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration | Q46688887 | ||
| Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer | Q47450132 | ||
| Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial | Q47599265 | ||
| A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer | Q48047005 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lorlatinib | Q27285820 |
| P304 | page(s) | 5093-5101 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date | |
| P478 | volume | 11 |
| Q64230139 | Comprehensive clinical implications of homeobox A10 in 3,199 cases of non-small cell lung cancer tissue samples combining qRT-PCR, RNA sequencing and microarray data |
| Q89622194 | Lorlatinib: an additional option for ALK-positive non-small cell lung cancer? |
| Q92236871 | Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives |
| Q92184046 | Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases |
| Q92141836 | Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients |
Search more.